certificate of analysis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-15. Anything still debated is marked as such rather than presented as settled.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
=== Radio === Following stints working in radio in Southern California and Honolulu, French became morning DJ on the Seattle radio station KIRO in 1959. He left KIRO in 1971 and moved to KVI, where he produced and wrote radio dramas. French was dismissed from his position at KVI in 1978, and he returned to KIRO in as a host 1980. He stepped down from his position as a host in 1994. In 1996, French began production of the radio drama program Imagination Theatre, which in 2003 moved to KIXI. His syndicated programs are now broadcast on over 120 stations in the U.S. and Canada and are also broadcast via XM Satellite Radio throughout North America. In January 2017, it was announced that, due to age and health issues, French and his family would be closing down their production company, Jim French Productions, and discontinuing all broadcasts of Imagination Theatre at the end of March 2017. Imagination Theatre was relaunched in 2019, following a successful crowdfunding campaign headed by actors and producers John Patrick Lowrie and Larry Albert, and is now produced by Aural Vision, LLC.
=== Other side effects === The most common side effects are skin related, such as rashes, photoallergy and (in rare cases) Stevens–Johnson syndrome. Less common side effects of chlorpropamide include gastrointestinal symptoms such as nausea, vomiting, and diarrhea. It may cause facial flushing after the ingestion of alcohol. In very high doses it can increase secretion of antidiuretic hormone (ADH), which can lead to hyponatremia. It also markedly raises the serum level of alkaline phosphatase.
On October 10, Trump had another visit with Walter Reed. Leavitt described the visit as a "routine yearly checkup", despite it being Trump's second at the facility in a six-month-period. Barbabella did not elaborate on the imaging or "preventive assessments" that he performed, but added that Trump's laboratory results were "exceptional," and that his cardiac age is "approximately 14 years younger than his chronological age." On October 27, Trump told reporters that he had undergone an undisclosed MRI scan during a previous visit to Walter Reed, which, despite his claim that it gave "some of the best reports for the age" and "some of the best reports they've ever seen", led to further speculation about his health due to the undisclosed nature of why he had the procedure done. Trump also bragged about his taking of the MoCA test, again misidentifying the screening assessment for detecting cognitive impairment as a "very hard [...] IQ test" and claiming that younger Democratic political opponents do not have the intelligence to pass it. Whether a third MoCA test was conducted during the October visit or if Trump was referring to his April 2025 and/or January 2018 assessments was not clarified. On October 28, new concerns about Trump's mental state were raised when a video emerged of him wandering off while walking alongside Sanae Takaichi, the first female prime minister of Japan, while at Akasaka Palace in Tokyo, Japan.
== Notable ascents == 1953 2nd ascent Yosemite Point Buttress. (With Royal Robbins) 1953 2nd ascent North Face Sentinel Rock. (With Royal Robbins and Don Wilson) 1953 Palisades Traverse Thunderbolt Peak to Mount Sill via North Palisade. (With Gary Hemming) 1954 5th ascent Lost Arrow Spire. (With Wayne Merry) 1955 3rd ascent Lost Arrow Chimney. (With Charles Wilts and Don Wilson) 1956 1st ascent Spider Rock, Canyon de Chelly National Monument, AZ, USA, March 30. (With Mark Powell and Don Wilson) 1956 1st ascent East Buttress of Middle Cathedral Rock, Yosemite National Park, CA, USA, June 16. (With Mark Powell and Don Wilson) 1956 5th ascent Castle Rock Spire. (With Charles Wilts) 1956 1st ascent Cleopatra's Needle, Valley of the Thundering Water, NM, USA, September 6. (With Mark Powell and Don Wilson) 1957 1st ascent The Step, Tahquitz Idyllwild, CA, USA, May 18. (With Royal Robbins) 1957 1st ascent Totem Pole, Monument Valley, AZ, USA. June 13. (With Bill Feuerer, Mark Powell, and Don Wilson) 1957 1st ascent Northwest Face of Half Dome, Yosemite, CA, USA, June 23–27. First grade VI climb in America. (With Mike Sherrick and Royal Robbins)
Sources: en.wikipedia.org
The three substrates of this enzyme are hydroxyacetylaminofluorene, reduced nicotinamide adenine dinucleotide (NADH), and a proton. Its products are 2-acetylaminofluorene, oxidised NAD+, and water. The enzyme can use nicotinamide adenine dinucleotide phosphate as an alternative cofactor. This enzyme belongs to the family of oxidoreductases, specifically those acting on other nitrogenous compounds as donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 2-acetamidofluorene:NAD(P)+ oxidoreductase. Other names in common use include N-hydroxy-2-acetylaminofluorene reductase, and NAD(P)H:N-hydroxy-2-acetamidofluorene N-oxidoreductase.
=== In relation with experience === Thomas Nagel has said that "There are elements which, if added to one's experience, make life better; there are other elements which if added to one's experience, make life worse. But what remains when these are set aside is not merely neutral: it is emphatically positive." Experiences are central to a proposed dimension of well-being called psychological richness. This additional dimension of well-being was proposed as an empirically supported expansion to the hedonic vs. eudaimonic well-being dichotomy. Whereas hedonic well-being can be measured via life satisfaction, and eudaimonic well-being can be measured via one's perceptions of the meaning of their life, psychological richness is measured via characteristic experiences. Psychological richness is cultivated through having psychologically rich experiences, which are characterized as varying, interesting, novel, challenging, and perspective-changing, as subjectively measured by the experiencer. One line of evidence for this comes from studies conducted with college students, where students who went on trips (new and unusual experiences), whether they be short excursions or semester-length study abroad programs, reported increased psychological richness, but not increases in happiness or meaning (Oishi et al., 2021). In contrast to hedonic well-being, which is thought to result in personal satisfaction, and eudaimonic well-being, which is thought to result in societal contribution, psychological richness is thought to result in wisdom.
Though the push-pull technique was invented as a strategy to control stem-boring moths, such as Chilo partellus, through the manipulation of volatile host-finding cues, it was later discovered that allelopathic substances exuded by the roots of Desmodium spp. also contribute to the suppression of the damaging parasitic weed, Striga.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.